SavedAdd your journal

Journals / Akdeniz Tıp Dergisi / 2015 / Cilt: 1 - Sayı: 1

Comparison of Calcineurin Inhibitors with M-Tor Inhibitors in Renal Transplant Patients

Böbrek Nakli Hastalarında Kalsinörin İnhibitörleri ile m-TOR İnhibitörlerinin Karşılaştırılması

Hüseyin KOÇAK
Gültekin SÜLEYMANLAR
Ramazan ÇETİNKAYA
F. Fevzi ERSOY
Ayhan DİNÇKAN
Vural Taner YILMAZ
Pages
50–57
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The PTDM ratio was higher in the first group p=0.001 . conclusion: We found that m-TORi are more effective than calcineurin inhibitors in terms of graft survival

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Our aim was to compare the efficacy and safety of calcineurin inhibitors with m-Tor inhibitors m-TORi in renal transplant patients.Material and Methods: We recruited 983 patients who had undergone renal transplantation between 2005 and 2009 at our center.
📊
Key Findings & Data:Group 1 consisted of 632 patients treated with a regimen including calcineurin inhibitors and Group 2 consisted of 351 patients treated with a regimen including m-TORi.
💡
Conclusion & Impact:The PTDM ratio was higher in the first group p=0.001 . conclusion: We found that m-TORi are more effective than calcineurin inhibitors in terms of graft survival
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Böbrek nakli · Takrolimus · Siklosporin

Abstract

Objective: Our aim was to compare the efficacy and safety of calcineurin inhibitors with m-Tor inhibitors m-TORi in renal transplant patients.Material and Methods: We recruited 983 patients who had undergone renal transplantation between 2005 and 2009 at our center. Patients were evaluated in two groups according to their immunosuppressive protocol. Group 1 consisted of 632 patients treated with a regimen including calcineurin inhibitors and Group 2 consisted of 351 patients treated with a regimen including m-TORi. The two groups were compared in terms of graft and patient survival times, rejection rates, delayed graft function DGF , chronic allograft dysfunction CAD , post transplant diabetes mellitus PTDM and graft functions.results: Demographic characteristics of the two groups were similar. The acute rejection rates and patient survival times were also similar, but the graft survival times were better in the second group p=0.007 . DGF, CAD and graft functions did not differ between the two groups. The PTDM ratio was higher in the first group p=0.001 . conclusion: We found that m-TORi are more effective than calcineurin inhibitors in terms of graft survival

Özet

amaç: Çalışmamızda böbrek nakli hastalarında kalsinörin inhibitörleri KNİ ile m-TORi’nin m-Target of Rapamisin İnhibitor etkinlik ve güvenilirliklerinin karşılaştırılması amaçlanmıştır. Gereç ve yöntemler: Çalışmaya 2005-2009 yılları arasında merkezimizde böbrek nakli yapılmış olan 983 hasta alındı. Hastalar immünosupresif tedavi protokollerine göre iki gruba ayrıldı. Grup 1: KNİ kullanılanlar: 632 hasta, Grup 2: m-TORi kullanılanlar: 351 hasta. Grupların greft ve hasta sağkalım süreleri, rejeksiyon oranları, gecikmiş greft fonksiyonu GGF , kronik allogreft disfonksiyon KAD , nakil sonrası gelişen diabetes mellitus NSDM ve greft fonksiyonları karşılaştırıldı. bulgular: Grupların demografik özellikleri benzerdi. Akut rejeksiyon oranları, hasta sağkalım süreleri, GGF, KAD ve greft fonksiyonlarının benzer, greft sağkalım süresinin ikinci grupta p= 0,007 , NSDM oranının ise 1.grupta p=0,001 daha yüksek olduğu tespit edildisonuç: M-TORi’nin greft sağkalımı açısından KNİ’den daha etkin olduğu gösterildi

🔖

Cite This Article

KOÇAK, H., SÜLEYMANLAR, G., ÇETİNKAYA, R., ERSOY, F. F., DİNÇKAN, A., YILMAZ, V. T. (2022). Comparison of Calcineurin Inhibitors with M-Tor Inhibitors in Renal Transplant Patients. Akdeniz Tıp Dergisi, Cilt: 1 - Sayı: 1, 50–57. https://ajindex.com/articles/434544

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: A role of aldosterone. Am J Physiol Renal Physiol 2007;293(1):2- 9
  2. Hortelano S, Castilla M, Torres AM, Tejedor A, Bosca L. Potentiation by nitric oxide of cyclosporin A and FK506- induced apoptosis in renal proximal tubule cells. J Am Soc Nephrol 2000;11:2315-23
  3. Yılmaz VT, Gürkan A, Süleymanlar İ, Dinçkan A, Koçak H, Ersoy FF, Yakupoğlu G, Süleymanlar G. Maintenance ımmunosuppressive therapy in renal transplantation: General considerations and Akdeniz University experience. Turkiye Klinikleri J Nephrol-Special Topics 2010;3:18-34
  4. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000;11:974-9
  5. Alexander RT, Hoenderop JG, Bindels RJ. Molecular determinants of magnesium homeostasis: Insights from human disease. J Am Soc Nephrol 2008;19:1451-8
  6. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroidfree immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005;79:807-14
  7. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group: Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002;74:1560-7
  8. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004;78:1362-6
  9. Letavernier E, Pe’raldi MN, Pariente A, Morelon E, Legendre C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005;80:1198-203
  10. Boratyńska M, Banasik M, Watorek E, Falkiewicz K, Patrzałek D, Szyber P, Klinger M. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006;38:101-4
  11. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N; DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. American Journal of Transplantation 2007;7:1506-14 12. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in pa